Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650® analyzer: Effect of phenytoin metabolite and analogue

Therapeutic Drug Monitoring

Volumn 27, Issue 3, 2005, Pages 305-308

  Datta, Pradip ^a   Scurlock, Deven ^b   Dasgupta, Amitava ^b  

^a BAYER CORPORATION   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cross reactivity; Fluorescence polarization immunoassay; Phenytoin; Turbidimetric immunoassay

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; ANTICONVULSIVE AGENT; BILIRUBIN; BILIRUBIN GLUCURONIDE; DRUG METABOLITE; INTRALIPID; OXAPROZIN; PHENYTOIN; PHENYTOIN DERIVATIVE; TRIACYLGLYCEROL;

ACCURACY; ANALYZER; ARTICLE; BLOOD SAMPLING; CLINICAL LABORATORY; CONCENTRATION (PARAMETERS); CROSS REACTION; DRUG DETERMINATION; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMOLYSIS; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; TURBIDIMETRY;

BILIRUBIN; CROSS REACTIONS; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMOLYSIS; HUMANS; NEPHELOMETRY AND TURBIDIMETRY; PHENYTOIN; PROPIONIC ACIDS;

EID: 20044364548     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000164315.13825.dd     Document Type: Article

References (20)

1. Putnam TJ, Merritt HH. Experimental determination of anticonvulsant properties of some phenyl derivatives. Acta Neurol. 1981;64:22-28.
2. Theodore WH. Rational use of antiepileptic drugs. Pharmacol Ther. 1992;54:297-305.
3. Thornbery JM, Groover RV. Grand mal epilepsy case history. Appl Ther Drug Monit. 1984;2:39-41.
4. Ayala GF, Johnston D. The influence of phenytoin on fundamental electric properties of simple nervous system. Epilepsia. 1977;18:299-307.
5. Delgado-Escueta AV, Horan MP. Phenytoin: biochemical membrane study. In: Glaser GH, Penry JK, Woodbury DM, eds. Antiepileptic Drugs: Mechanism of Action. Advances in Neurology, vol 27. New York: Raven Press, 1980:377-398.
6. Melikian AP, Straughn AB, Sylwka GWA, et al. Bioavailability of 11 phenytoin products. J Pharmacokinet Biopharm. 1977;5:133-146.
7. Theodore WH, Qu ZP, Tsay JY. Phenytoin: the pseudo steady-state phenomenon. Clin Pharmacol Ther. 1984;35:822-825.
8. Mullen PW. Optimal phenytoin therapy: a new technique for individualizing dosage. Clin Pharmacol Ther. 1978;23:228-232.
9. Wilder BJ, Serrano EE, Ramsay RE. Plasma diphenylhydantoin levels after loading and maintenance doses. Clin Pharmacol Ther. 1973;14:798-801.
10. Burni J. Phenytoin. In: Taylor WJ, Diers CMH, eds. A Text Book for the Clinical Application of Therapeutic Drug Monitoring. Irvine, TX: Abbott Laboratories Diagnostics Division, 1986:253-267.
11. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacol Ther. 1979;4:153-169.
12. Haidukewych D, Rodin EA. Serial free and plasma valproic acid and phenytoin monitoring and drug interactions. Ther Drug Monit. 1981;3:303-307.
13. Roberts WL, Rainey PM. Interference in immunoassay measurements of total and free phenytoin in uremic patients: a reapprisal. Clin Chem. 1993;39:1872-1877.
14. Eadie MJ. Laboratory control of anticonvulsant dosage. Drugs. 1974;8:386-397.
15. Datta P. Oxaprozin and 5-(p-hydroxyphenyl)-5-phenylhydantoin interference in phenytoin immunoassays. Clin Chem. 1997;43:1468-1469.
16. Dasgupta A, Datta P, Redlich G, et al. Analytical performance of a new chemiluminescent phenytoin assay. Ther Drug Monit. 1997;19:191-194.
17. Miller JJ, Valdes R. Methods for calculating cross reactivity in immunoassays. J Clin Immunoassays. 1992;15:97-100.
18. Datta P, Dasgupta A. Analytical performance evaluation of a new turbidimetric immunoassay for valproic acid on the ADVIA 1650 analyzer: effect of gross hemolysis and high bilirubin. J Clin Lab Anal. 2005;19:31-35.
19. Dasgupta A, Datta P. Analytical performance evaluation of a new turbidimetric immunoassay for carbamazepine on the ADVIA 1650 analyzer: effect of carbamazepine 10,11-epoxide. Ther Drug Monit. 2005;27:31-34.
20. Datta P, Dasgupta A. A new turbidimetric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone. Ther Drug Monit. 2003;25:478-482.